Accueil   Diary - News   All news GeNeuro Initiates Phase 2a Study with GNbAC1 in Type 1 Diabetes in Australia

GeNeuro Initiates Phase 2a Study with GNbAC1 in Type 1 Diabetes in Australia

Geneva, Switzerland, 18 April 2017 - 7:30am CEST - GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiation of a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D).

 

GNbAC1 is a monoclonal antibody designed to neutralise MSRV-Env, a pathogenic protein that has been detected in the pancreas of T1D patients. GeNeuro is already evaluating GNbAC1 in Phase 2 clinical studies in patients with multiple sclerosis (MS), a disease in which evidence shows MSRV-Env to be a potential causal factor.

 

 

 

Read the press release